Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience Cover

.blurhash-client-img { display: none !important; }

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

European Pharmaceutical Journal

Volume 69 (2022): Issue s1 (July 2022)

By: Jan Juřica, Roman Goněc, Adela Bártová and Jana Gregorová

Open Access

|Jun 2022

Authors

Jan Juřica

jurica@med.muni.cz

Faculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech Republic

Masaryk Memorial Cancer Institute, Brno, Czech Republic

Faculty of Pharmacy, Department of Pharmacology and Toxicology, Masaryk University, Brno, Czech Republic

Roman Goněc

Masaryk Memorial Cancer Institute, Brno, Czech Republic

Adela Bártová

Faculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech Republic

Jana Gregorová

Faculty of Medicine, Department of Biochemistry, Masaryk University, Brno, Czech Republic

DOI: https://doi.org/10.2478/afpuc-2022-0006 | Journal eISSN: 2453-6725

Journal RSS Feed

Language: English

Page range: 84 - 86

Submitted on: Apr 25, 2022

|

Accepted on: May 10, 2022

|

Published on: Jun 18, 2022

Published by: Comenius University in Bratislava, Faculty of Pharmacy

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

Immune checkpoint inhibitors,

adverse effect,

Related subjects:

Pharmacy, other

© 2022 Jan Juřica, Roman Goněc, Adela Bártová, Jana Gregorová, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 69 (2022): Issue s1 (July 2022)Next article